Bidirectional Association Between Alopecia Areata and Prurigo Nodularis: a Population-based Cohort Study Using TriNetX
Overview
Overview
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
References
1.
Renert-Yuval Y, Pavel A, Del Duca E, Facheris P, Pagan A, Bose S
. Scalp biomarkers during dupilumab treatment support Th2 pathway pathogenicity in alopecia areata. Allergy. 2022; 78(4):1047-1059.
PMC: 11344221.
DOI: 10.1111/all.15561.
View
2.
Ma F, Gharaee-Kermani M, Tsoi L, Plazyo O, Chaskar P, Harms P
. Single-cell profiling of prurigo nodularis demonstrates immune-stromal crosstalk driving profibrotic responses and reversal with nemolizumab. J Allergy Clin Immunol. 2023; 153(1):146-160.
PMC: 11231883.
DOI: 10.1016/j.jaci.2023.07.005.
View
3.
Yosipovitch G, Mollanazar N, Stander S, Kwatra S, Kim B, Laws E
. Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials. Nat Med. 2023; 29(5):1180-1190.
PMC: 10202800.
DOI: 10.1038/s41591-023-02320-9.
View
4.
Roh Y, Marani M, Choi U, Sutaria N, Parthasarathy V, Deng J
. Validation of International Classification of Diseases Tenth Revision code for prurigo nodularis. J Am Acad Dermatol. 2021; 87(2):482-484.
DOI: 10.1016/j.jaad.2021.10.026.
View